瞄准:在老鼠在 acute-on-chronic 肝失败(ACLF ) 上调查乙醇 pyruvate (EP ) 的保护的效果。方法:一个 ACLF 模型在老鼠被建立,并且动物随机被划分成正常,模型和 EP 治疗组。在 EP 治疗的老鼠在 ACLF 的正式就职以后在 3 h, 6 h, 12 h 和 24 h 组织收到的 EP (40 mg/kg ) 。浆液内毒素,高活动性组 box-1 ( HMGB1 ),丙氨酸 transaminase (中高音),肿瘤坏死因素--(TNF-),干扰素--(IFN-), interleukin ( IL ) -10 和 IL-18 层次,在肝纸巾的肝组织学和 HMGB1 表情的变化在 ACLF 的正式就职以后在 48 h 被检测。ACLF 老鼠的幸存上的 EP 的效果也被观察。结果:内毒素的浆液层次(0.394 映獩畴慬?$
AIM: To investigate the protective effects of ethyl py- ruvate (EP) on acute-on-chronic liver failure (ACLF) in rats. METHODS: An ACLF model was established in rats, and animals were randomly divided into normal, mod- el and EP treatment groups. The rats in EP treatment group received EP (40 mg/kg) at 3 h, 6 h, 12 h and 24 h after induction of ACLF. Serum endotoxin, high mobility group box-1 (HMGB1), alanine transaminase (ALT), tumor necrosis factor-α (TNF-α), interferon-α (IFN-γ), interleukin (IL)-10 and IL-18 levels, changes of liver histology and HMGB1 expressions in liver tis- sues were detected at 48 h after induction of ACLF. The effects of EP on the survival of ACLF rats were also observed.RESULTS: Serum levels of endotoxin (0.394 ± 0.066 EU/mL vs 0.086±0.017 EU/mL, P 〈 0.001), HMGB1 (35.42±10,86 μg/L vs 2.14 ± 0.27 μg/L, P 〈 0.001), ALT (8415.87 ± 3567.54 IU/L vs 38.64 ± 8.82 IU/L, P 〈 0.001), TNF-α (190.77 ± 12.34 ng/L vs 124.40 ± 4.12 ng/L, P 〈 0.001), IFN-γ (715.38 ± 86.03 ng/L vs 398.66 ± 32.91 ng/L, P 〈 0.001), IL-10 (6.85 ± 0.64 ng/L vs 3.49 ± 0.24 ng/L, P 〈 0.001) and IL-18 (85.19 ±3.49 ng/L vs 55.38 ±1.25 ng/L, P 〈 0.001) were significantly increased, and liver tissues presented se- vere pathological injury in the model group compared with the normal group, Howeverr EP administration significantly improved hepatic histopathology and re- duced the serum levels of endotoxin (0.155±0.045 EU/mL vs 0.394 ± 0.066 EU/mL vs P 〈 0.001) and in- flammatory cytokines (11.13 ± 2.58 μg/L vs 35.42 ± 10.86 μg/L for HMGB1, 3512.86 ± 972.67 IU/L vs 8415.87 ± 3567.54 IU/L for ALT, 128.55 ± 5.76 ng/L vs 190.77 ± 12.34 ng/L for TNF-α 438.16 ± 38.10 ng/L vs 715.38 ± 86.03 ng/L for IFN-γ 3.55 ± 0.36 ng/L vs 6.85 ± 0.64 ng/L for IL-10, and 60.35 ± 1.63 ng/L vs 85.19 ± 3.49 ng/L for IL-18, respectively, P 〈 0.001), and the levels of HMGB1 in liver tissues re- gardless of treatment time after